Better Therapeutics, Inc.

Better Therapeutics, Inc. (Nasdaq: BTTX) is a digital therapeutics company that entered the public markets through its merger with Mountain Crest Acquisition Corp. II, a blank-check company sponsored by Mountain Crest Capital LLC, with the business combination closing in 2021. Operating in the healthcare technology sector, the company focused on developing prescription digital therapeutics targeting cardiometabolic diseases, including its lead candidate designed to treat type 2 diabetes. By late 2023, the company announced a wind-down of its operations amid sustained financial pressures, and its March 2024 Form 424B3 prospectus filing reflects activity during that dissolution period. Visit SpacDesk and sign up for full data, filings, and sponsor intelligence on BTTX and hundreds of other SPAC transactions.